Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Clint A Stalnecker

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Molecular Cell|July 21, 2023
KRAS regulation of miRNA: Stepping on the brake to go fasterClint A Stalnecker, Channing J Der
Science Signaling|March 27, 2020
RAS, wanted dead or alive: Advances in targeting RAS mutant cancersClint A Stalnecker, Channing J Der
The Journal of Biological Chemistry|February 16, 2017
Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activatorsClint A Stalnecker, Jon W Erickson, Richard A Cerione
Autophagy|February 24, 2022
Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancerClint A Stalnecker, Michael F Coleman, Kirsten L Bryant
The Journal of Biological Chemistry|December 25, 2019
The activation loop and substrate-binding cleft of glutaminase C are allosterically coupledYunxing Li, Sekar Ramachandran, Thuy-Tien T Nguyen, et al.
The Journal of Biological Chemistry|August 21, 2016
Mechanistic Basis of Glutaminase Activation: A KEY ENZYME THAT PROMOTES GLUTAMINE METABOLISM IN CANCER CELLSYunxing Li, Jon W Erickson, Clint A Stalnecker, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2014
Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cellsClint A Stalnecker, Scott M Ulrich, Yunxing Li, et al.
The Journal of Clinical Investigation|December 2, 2025
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancerZheng Zhong, Xinang Cao, Pei-Ju Liao, et al.
Genes & Cancer|March 16, 2023
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in <i>KRAS</i>-mutant pancreatic cancerYe S Lee, Jennifer E Klomp, Clint A Stalnecker, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinomaMallory K Roach, Seamus E Degan, Jonathan M DeLiberty, et al.
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Molecular Cell|July 21, 2023
KRAS regulation of miRNA: Stepping on the brake to go fasterClint A Stalnecker, Channing J Der
Science Signaling|March 27, 2020
RAS, wanted dead or alive: Advances in targeting RAS mutant cancersClint A Stalnecker, Channing J Der
The Journal of Biological Chemistry|February 16, 2017
Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activatorsClint A Stalnecker, Jon W Erickson, Richard A Cerione
Autophagy|February 24, 2022
Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancerClint A Stalnecker, Michael F Coleman, Kirsten L Bryant
The Journal of Biological Chemistry|December 25, 2019
The activation loop and substrate-binding cleft of glutaminase C are allosterically coupledYunxing Li, Sekar Ramachandran, Thuy-Tien T Nguyen, et al.
The Journal of Biological Chemistry|August 21, 2016
Mechanistic Basis of Glutaminase Activation: A KEY ENZYME THAT PROMOTES GLUTAMINE METABOLISM IN CANCER CELLSYunxing Li, Jon W Erickson, Clint A Stalnecker, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 31, 2014
Mechanism by which a recently discovered allosteric inhibitor blocks glutamine metabolism in transformed cellsClint A Stalnecker, Scott M Ulrich, Yunxing Li, et al.
The Journal of Clinical Investigation|December 2, 2025
Oncogenic KRAS/ERK/JUNB signaling suppresses differentiation regulator GATA6 in pancreatic cancerZheng Zhong, Xinang Cao, Pei-Ju Liao, et al.
Genes & Cancer|March 16, 2023
VCP/p97, a pleiotropic protein regulator of the DNA damage response and proteostasis, is a potential therapeutic target in <i>KRAS</i>-mutant pancreatic cancerYe S Lee, Jennifer E Klomp, Clint A Stalnecker, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2026
Vertical inhibition of the autophagy pathway impairs growth and enhances sensitivity to mTORC1 inhibition in pancreatic ductal adenocarcinomaMallory K Roach, Seamus E Degan, Jonathan M DeLiberty, et al.
Pageof 3